Propranolol Hydrochloride
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Propranolol Hydrochloride |
| DrugBank ID | DB00571 |
| Brand Names (EU) | Hemangiol |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.40% |
Approved Indication (EMA)
Hemangiol is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy: Life- or function-threatening haemangioma, Ulcerated haemangioma with pain and/or lack of response to simple wound care measures, Haemangioma with a risk of permanent scars or disfigurement. It is to be initiated in infants aged 5 weeks to 5 months.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | distal myopathy, Tateyama type | 99.40% | DL |
| 2 | congenital myopathy with excess of thin filaments | 99.30% | DL |
| 3 | hypertrophic cardiomyopathy | 99.29% | DL |
| 4 | glomus tumor | 99.29% | DL |
| 5 | hemangioma | 99.24% | DL |
| 6 | primary intralymphatic angioendothelioma | 99.22% | DL |
| 7 | hypertrophic cardiomyopathy due to intensive athletic training | 99.17% | DL |
| 8 | chondroma | 99.14% | DL |
| 9 | cirrhotic cardiomyopathy | 99.12% | DL |
| 10 | cardiomyopathy | 99.12% | DL |
| 11 | spindle cell hemangioma | 99.12% | DL |
| 12 | His bundle tachycardia | 99.09% | DL |
| 13 | retinal capillary malformation | 99.09% | DL |
| 14 | intramuscular hemangioma | 98.97% | DL |
| 15 | Maffucci syndrome | 98.97% | DL |
| 16 | congenital hemangioma | 98.93% | DL |
| 17 | breast epithelioid hemangioma | 98.91% | DL |
| 18 | breast capillary hemangioma | 98.90% | DL |
| 19 | PTEN hamartoma tumor syndrome | 98.88% | DL |
| 20 | cutaneous glomangioma | 98.88% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.